Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental hepatitis b drug shows promise in early trial

NCT ID NCT02577029

Terminated Disease control Sponsor: Arrowhead Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called ARC-520 in 79 people with chronic hepatitis B. Some participants received ARC-520 alone, while others got it combined with standard treatments like entecavir or tenofovir. The goal was to see if ARC-520 could lower hepatitis B surface antigen levels and to check for side effects. The trial was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ARC-520 (a gene-silencing drug given intravenously)

What this could lead to

If successful, this could point toward a new way to control chronic hepatitis B by reducing viral surface antigen levels.

What could go wrong

This trial was terminated early, so results are limited. It is a Phase 2 study with only 79 participants, and the drug may cause side effects like infusion reactions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection hepatitis D virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS B HEPATITIS D

Contacts and locations

Locations

  • Research Site 1

    Westmead, New South Wales, 2145, Australia

  • Research Site 10

    Sofia, 1431, Bulgaria

  • Research Site 11

    Sofia, 1463, Bulgaria

  • Research Site 12

    Varna, 9020, Bulgaria

  • Research Site 13

    Pleven, 5800, Bulgaria

  • Research Site 14

    Hong Kong, China

  • Research Site 15

    Seoul, 6273, South Korea

  • Research Site 16

    Daegu, 41944, South Korea

  • Research Site 17

    Busan, 49241, South Korea

  • Research Site 18

    Seoul, 3080, South Korea

  • Research Site 19

    Busan, South Korea

  • Research Site 2

    Parkville, Victoria, 3052, Australia

  • Research Site 20

    Seoul, South Korea

  • Research Site 21

    Auckland, 1010, New Zealand

  • Research Site 23

    Papatoetoe, Aukland, 2025, New Zealand

  • Research Site 24

    Dunedin, Otago-Southland, New Zealand

  • Research Site 25

    Chisinau, MD-2004, Moldova

  • Research Site 26

    Changhua, 500, Taiwan

  • Research Site 27

    Douliu, Yunlin County, 640, Taiwan

  • Research Site 28

    Kaohsiung City, 807, Taiwan

  • Research Site 29

    Bangkok, 10330, Thailand

  • Research Site 3

    Camperdown, New South Wales, 2050, Australia

  • Research Site 30

    Bangkok, 10400, Thailand

  • Research Site 31

    Khon Kaen, 40002, Thailand

  • Research Site 32

    Bangkok, 10400, Thailand

  • Research Site 33

    Chiang Mai, 50200, Thailand

  • Research Site 34

    Pathum Thani, 12120, Thailand

  • Research Site 4

    Fitzroy, Victoria, 3065, Australia

  • Research Site 5

    Darlinghurst, New South Wales, 2010, Australia

  • Research Site 6

    Clayton, Victoria, 3168, Australia

  • Research Site 7

    Nedlands, Washington, 6009, Australia

  • Research Site 8

    Concord, New South Wales, 2139, Australia

  • Research Site 9

    Adelaide, South Australia, 5000, Australia